Lupus eritematoso sistémico de debut atípico: a propósito de 3 casos

Barrio Nogal, Laura; Clemente Garulo, Daniel; Lucas Collantes, Carmen de; Aparicio López, Cristina; López Robledillo, Juan Carlos.
An. pediatr. (2003. Ed. impr.) ; 93(4): 257-259, oct. 2020. ilus
Artículo en Español | IBECS (España) | ID: ibc-201500

Documentos relacionados

  1. Adipokine interactions promote the pathogenesis of systemic lupus erythematosus.
  2. Autoantibody and Cytokine Profiles during Treatment with Belimumab in Patients with Systemic Lupus Erythematosus.
  3. Rituximab: an emerging treatment for recurrent diffuse alveolar hemorrhage in systemic lupus erythematosus.
  4. Principal component analysis reveals disconnect between regulatory cytokines and disease activity in Systemic Lupus Erythematosus.
  5. The role of IgG4 in systemic lupus erythematosus: Implications for pathogenesis and therapy.
  6. Systemic lupus erythematosus with ADAMTS13 inhibitor-negative thrombotic microangiopathy treated with combination of mycophenolate mofetil, plasma exchange and steroid.
  7. Circulating CD138 enhances disease progression by augmenting autoreactive antibody production in a mouse model of systemic lupus erythematosus.
  8. Development of an instrument to predict proliferative histological class in lupus nephritis based on clinical and laboratory data.
  9. Systemic chloroquine intoxication: a hint from the peripheral blood smear.
  10. Janus kinase inhibition in complement component 1 deficiency.